Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02560779 · ClinicalTrials.gov registry record · Phase 1
Trial of TRC105 and Sorafenib in Patients With HCC
A Phase 1 study, sponsored by Tracon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT02560779 is a Phase 1 study that has completed, run by Tracon Pharmaceuticals. The registered enrollment target is 27 participants.
The verdict
NCT02560779, a Phase 1 study, has completed, sponsored by Tracon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of the phase 1b portion is to evaluate safety and tolerability and determine a recommended phase 2 dose for TRC105 when added to standard dose sorafenib in patients with hepatocellular carcinoma. Up to 18 patients will be treated. The purpose of the phase 2 portion is to estimate the ORR of patients with hepatocellular carcinoma by RECIST 1.1. Up to 21 patients will be treated in phase 2.
Interventions
- DRUG Sorafenib
- DRUG Carotuximab (TRC105)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2016-11 |
| Est. Completion | 2019-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02560779
The ClinicalTrials.gov registry entry for NCT02560779 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tracon Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT02560779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02560779 about?
NCT02560779 is a clinical study titled "Trial of TRC105 and Sorafenib in Patients With HCC". The purpose of the phase 1b portion is to evaluate safety and tolerability and determine a recommended phase 2 dose for TRC105 when added to standard dose sorafenib in patients with hepatocellular carcinoma. Up to 18 patients will be treated. The purpose of the phase 2 portion is to estimate the OR...
What is the current status of trial NCT02560779?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2016-11. Estimated completion is 2019-08.
What interventions are being tested in trial NCT02560779?
The interventions under investigation include: Sorafenib (DRUG), Carotuximab (TRC105) (DRUG).
Who is sponsoring clinical trial NCT02560779?
This trial is sponsored by Tracon Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.